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Summary of Revisions for the 2009
Clinical Practice Recommendations
B
eginning with the 2005 supple-
ment, the Clinical Practice Recom-
mendations contained only the
“Standards of Medical Care in Diabetes”
and selected other position statements.
This change was made to emphasize the
importance of the “Standards” as the best
source to determine American Diabetes
Association (ADA) recommendations.
The position statements in the supple-
ment are updated yearly. Position state-
ments not included in the supplement
will be updated as necessary and repub-
lishedwhenupdated.Alistoftheposition
statements not included in this supple-
ment appears on p. S98.
Additions to the “Standards of
Medical Care in Diabetes”
● A section on bariatric surgery has been
added.
● A section on discharge planning has
beenaddedto“Diabetescareinthehos-
pital.”
Revisions to the “Standards of
Medical Care in Diabetes”
● In the “Testing for type 2 diabetes
in children” section, small-for-
gestational-age birth weight has been
added to the list of conditions associ-
ated with insulin resistance.
● Testing should begin at age 10 years or
at onset of puberty, if puberty occurs at
a younger age, and should be repeated
every 3 years. (E)
● In the “Prevention/delay of type 2 dia-
betes” section, the recommendation
hasbeenrevisedtoclarifythatone-time
counseling is not adequate.
● Patients with impaired glucose toler-
ance(A)orimpairedfastingglucose(E)
should be referred to an effective ongo-
ing support program for weight loss of
5–10% of body weight and for increas-
ing physical activity to at least 150 min
per week of moderate activity such as
walking.
Diabetes care:
● For patients using less frequent insulin
injections, noninsulin therapies, or
medical nutrition therapy and physical
therapy alone, self-monitoring of blood
glucose (SMBG) may be useful as a
guide to the success of therapy. (E)
● In the “Glucose monitoring” section,
continuous glucose monitoring (CGM)
has been revised with recommenda-
tions.
● CGM in conjunction with intensive
insulin regimens can be a useful tool
to lower A1C in selected adults (aged
25 years) with type 1 diabetes (A).
● Although the evidence for A1C low-
ering is less strong in children, teens,
and younger adults, CGM may be
helpful in these groups. Success cor-
relateswithadherencetoongoinguse
of the device. (C)
● CGM may be a supplemental tool to
SMBG in those with hypoglycemia
unawareness and/or frequent hypo-
glycemic episodes. (E)
● Table 8, now titled “Correlation of A1C
with average glucose,” has been revised
to reﬂect the correlation from the
ADAG (A1c-Derived Average Glucose)
study.
● The “Glycemic control” section has
been extensively revised based on new
evidence and includes the following
recommendations.
● Lowering A1C to below or around
7% has been shown to reduce micro-
vascular and neuropathic complica-
tions of type 1 and type 2 diabetes.
Therefore, for microvascular disease
prevention, the A1C goal for non-
pregnant adults in general is 7%.
(A)
● In type 1 and type 2 diabetes, ran-
domizedcontrolledtrialsofintensive
versus standard glycemic control
have not shown a signiﬁcant reduc-
tion in cardiovascular disease (CVD)
outcomes during the randomized
portion of the trials. Long-term fol-
low-up of the Diabetes Control and
Complications Trial (DCCT) and the
UK Prospective Diabetes Study (UK-
PDS) cohorts suggests that treatment
toA1Ctargetsbeloworaround7%in
the years soon after the diagnosis of
diabetes is associated with long-term
reduction in risk of macrovascular
disease. Until more evidence be-
comes available, the general goal of
7% appears reasonable for many
adults for macrovascular risk reduc-
tion. (B)
● Subgroup analyses of clinical trials
such as the DCCT and UKPDS and
the microvascular evidence from the
Action in Diabetes and Vascular Dis-
ease: Preterax and Diamicron MR
Controlled Evaluation (ADVANCE)
trial suggest a small but incremental
beneﬁt in microvascular outcomes
with A1C values closer to normal.
Therefore, for selected individual pa-
tients, providers might reasonably
suggest even lower A1C goals than
thegeneralgoalof7%,ifthiscanbe
achieved without signiﬁcant hypo-
glycemia or other adverse effects of
treatment. Such patients might in-
cludethosewithshortdurationofdi-
abetes, long life expectancy, and no
signiﬁcant CVD. (B)
● Conversely, less stringent A1C goals
than the general goal of 7% may be
appropriate for patients with a
history of severe hypoglycemia, lim-
itedlifeexpectancy,advancedmicro-
or macrovascular complications, and
extensive comorbid conditions and
those with longstanding diabetes in
whom the general goal is difﬁcult to
attain despite diabetes self-
management education, appropriate
glucose monitoring, and effective
doses of multiple glucose-lowering
agents including insulin. (C)
● The level of evidence for a medical
nutrition therapy recommendation
has been changed.
● Intake of trans fat should be mini-
mized. (B)
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contains the following recommenda-
tions.
● Bariatric surgery should be consid-
ered for adults with BMI 35 kg/m
2
and type 2 diabetes, especially if the
diabetes is difﬁcult to control with
lifestyle and pharmacologic therapy.
(B)
● Patients with type 2 diabetes who
have undergone bariatric surgery
need life-long lifestyle support and
medical monitoring. (E)
● Althoughsmalltrialshaveshowngly-
cemic beneﬁt of bariatric surgery in
patientswithtype2diabetesandBMI
30–35 kg/m
2, there is currently in-
sufﬁcient evidence to generally rec-
ommend surgery in patients with
BMI 35 kg/m
2 outside of a research
protocol. (E)
● The long-term beneﬁts, cost-
effectiveness, and risks of bariatric
surgery in individuals with type 2 di-
abetes should be studied in well-
designed randomized controlled
trials with optimal medical and life-
style therapy as the comparator. (E)
● The recommendation for pneumococ-
cal vaccination has been revised.
● Administer pneumococcal polysac-
charide vaccine to all diabetic pa-
tients 2 years of age. A one-time
revaccination is recommended for
individuals 64 years of age previ-
ously immunized when they were
65 years of age if the vaccine was
administered5yearsago.Otherin-
dications for repeat vaccination in-
clude nephrotic syndrome, chronic
renal disease, and other immuno-
compromised states, such as after
transplantation. (C)
Prevention and Management of
Diabetes Complications:
● Glomerular ﬁltration rate (GFR) cut
pointsforuseofthiazideorloopdiuret-
ics have been revised.
● Pharmacologic therapy for patients
with diabetes and hypertension
should be with a regimen that in-
cludes either an ACE inhibitor or an
angiotensin receptor blocker. If one
classisnottolerated,theothershould
be substituted. If needed to achieve
blood pressure targets, a thiazide di-
uretic should be added to those with
an estimated GFR (see below) 30
ml/min per 1.73 m
2 and a loop di-
uretic for those with an estimated
GFR 30 ml/min per 1.73 m
2.( C )
● Severaldyslipidemiarecommendations
have been revised.
● If drug-treated patients do not reach
the above targets on maximal toler-
ated statin therapy, a reduction in
LDL cholesterol of 30–40% from
baseline is an alternative therapeutic
goal. (A)
● If targets are not reached on maxi-
mally tolerated doses of statins, com-
bination therapy using statins and
other lipid-lowering agents may be
considered to achieve lipid targets
but have not been evaluated in out-
come studies for either CVD out-
comes or safety. (E)
● Severalantiplateletagentrecommenda-
tions have been revised and/or the level
of evidence has been changed.
● Use aspirin therapy (75–162 mg/
day) as a primary prevention strategy
inthosewithtype1ortype2diabetes
at increased cardiovascular risk, in-
cluding those who are 40 years of
age or who have additional risk fac-
tors (family history of CVD, hyper-
tension, smoking, dyslipidemia, or
albuminuria). (C)
● For patients with CVD and docu-
mented ASA (acetylsalicylic acid, as-
pirin) allergy, clopidogrel (75 mg/
day) should be used. (B)
● Combination therapy with aspirin
(75–162 mg/day) and clopidogrel
(75 mg/day) is reasonable for up to a
year after an acute coronary syn-
drome. (B)
● Coronary heart disease treatment rec-
ommendations have been revised
and/or the level of evidence has been
changed.
● In patients with known CVD, ACE
inhibitor (C), aspirin (A), and statin
therapy (A) (if not contraindicated)
should be used to reduce the risk of
cardiovascular events.
● In patients 40 years of age with an-
other cardiovascular risk factor (hy-
pertension, family history,
dyslipidemia, microalbuminuria,
cardiac autonomic neuropathy, or
smoking), aspirin and statin therapy
(if not contraindicated) should be
used to reduce the risk of cardiovas-
cular events. (B)
● In patients with coronary heart fail-
ure (CHF), thiazolidinedione use is
contraindicated. (C)
● Metformin may be used in patients
with stable CHF if renal function is
normal. It should be avoided in un-
stable or hospitalized patients with
CHF. (C)
● The recommendation in the “Retinopa-
thy screening and treatment” section
has been revised.
● Adults and children aged 10 years or
older with type 1 diabetes should
have an initial dilated and compre-
hensive eye examination by an oph-
thalmologist or optometrist within 5
years after the onset of diabetes. (B)
● One recommendation in the “Neurop-
athy screening and treatment” section
has been moved to the “Foot care” sec-
tion, and one has been revised.
● Screening for signs and symptoms of
cardiovascular autonomic neuropa-
thy should be instituted at diagnosis
of type 2 diabetes and 5 years after
the diagnosis of type 1 diabetes. Spe-
cial testing is rarely needed and may
not affect management or outcomes.
(E)
● The “Foot care” section has been exten-
sively revised, including the recom-
mendations.
● For all patients with diabetes, per-
form an annual comprehensive foot
examination to identify risk factors
predictiveofulcersandamputations.
The foot examination should include
inspection,assessmentoffootpulses,
and testing for loss of protective sen-
sation (10-g monoﬁlament plus test-
ing any one of: vibration using
128-Hz tuning fork, pinprick sensa-
tion, ankle reﬂexes, or vibration per-
ception threshold). (B)
Diabetes Care in Speciﬁc
Populations:
● Blood pressure treatment recommen-
dations for children with type 1 diabe-
tes have been modiﬁed.
● Treatment of high-normal blood
pressure (systolic or diastolic blood
pressure consistently between the
90–95th percentile for age, sex, and
height) should include dietary inter-
vention and exercise aimed at weight
control and increased physical activ-
ity, if appropriate. If target blood
pressure is not reached with 6–12
months of lifestyle intervention,
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initiated (E).
● Pharmacologic treatment of high
blood pressure (systolic or diastolic
blood pressure consistently above
the 95th percentile for age, sex, and
height or consistently 130/80
mmHg for adolescents) should be
initiatedalongwithlifestyleinterven-
tion as soon as the diagnosis is con-
ﬁrmed. (E)
● The goal of treatment is a blood pres-
sure consistently 130/80 or below
the 90th percentile for age, sex, and
height, whichever is lower. (E)
● Recommendations on celiac disease
screening in children with type 1 dia-
betes have been revised.
● Patients with type 1 diabetes should
bescreenedforceliacdiseasebymea-
suring tissue transglutaminase or
anti-endomysial antibodies, with
documentation of normal serum IgA
levels, soon after the diagnosis of di-
abetes. (E)
● Testing should be repeated if growth
failure, failure to gain weight, weight
loss, or gastroenterologic symptoms
occur. (E)
● Consideration should be given to pe-
riodic re-screening of asymptomatic
individuals. (E)
● The recommendation on preconcep-
tion care has been revised.
● Starting at puberty, preconception
counselingshouldbeincorporatedin
the routine diabetes clinic visit for all
women of child-bearing potential.
(C)
Diabetes care in speciﬁc settings:
● The “Diabetes care in the hospital” sec-
tion has been signiﬁcantly revised, and
recommendations for glucose goals
have been revised.
● Critically ill surgical patients’ blood
glucose levels should be kept as close
to 110 mg/dl (6.1 mmol/l) as possi-
ble, and generally 140 mg/dl (7.8
mmol/l). (A) These patients require
an intravenous insulin protocol that
has demonstrated efﬁcacy and safety
in achieving the desired glucose
range without increasing risk for se-
vere hypoglycemia. (E)
● Criticallyillnonsurgicalpatients’gly-
cemictargetsarelesswelldeﬁned.In-
travenous insulin infusion protocols
targeting blood glucose levels
110–140 mg/dl have been shown
to reduce morbidity and mortality in
some but not all studies. Intravenous
insulin infusion protocols that effec-
tively and safely keep blood glucose
140 mg/dl are recommended. (C)
● The “Diabetes care in the school and
day care setting” section has been re-
vised, including the recommendations.
● An individualized Diabetes Medical
Management Plan (DMMP) should
be developed by the parent/guardian
and the student’s personal diabetes
health care team with input from the
parent/guardian. (E)
● All school staff members who have
responsibility for a student with dia-
betes should receive training that
provides a basic understanding of di-
abetes and a student’s needs. (E)
● While the school nurse is the coordi-
nator and primary provider of diabe-
tes care, a small number of school
personnel should be trained in rou-
tine and emergency diabetes proce-
dures(includingmonitoringofblood
glucose levels and administration of
insulin and glucagon) and in the ap-
propriate response to high and low
blood glucose levels and should per-
form these diabetes care tasks when
theschoolnurseisnotavailabletodo
so. These school personnel need not
be health care professionals. (E)
● As speciﬁed in the DMMP and as de-
velopmentally appropriate, the stu-
dent with diabetes should have
immediate access to diabetes sup-
plies at all times and should be per-
mitted to self-manage his or her
diabetes in the classroom or any-
wherethestudentmaybeinconjunc-
tion with a school activity. Such self-
management should include blood
glucose monitoring and responding
to blood glucose levels with needed
food and medication. (E)
● The “Hypoglycemia and employment/
licensure” section has been renamed
“Diabetes and employment” and con-
tains new recommendations.
● Whenquestionsariseaboutthemed-
ical ﬁtness of a person with diabetes
for a particular job, a health care pro-
fessional with expertise in treating
diabetes should perform an individ-
ualized assessment; input from the
treating physician should always be
included. (E)
● Proper safety assessments for em-
ployment should include review of
blood glucose test results, history of
severe hypoglycemia, presence of
hypoglycemia unawareness, and
presence of diabetes-related compli-
cations but should not include urine
glucose or A1C/eAG (estimated aver-
age glucose) tests or be based on a
generalassessmentoflevelofcontrol.
(E)
Other revisions to the 2009 Clinical
Practice Recommendations
● The “Diabetes in the School and Day
Care Setting” position statement has
been signiﬁcantly revised.
● The position statement previously ti-
tled “Hypoglycemia and Employment/
Licensure” has been renamed “Diabetes
and Employment.” It has been exten-
sively revised and expanded, in part to
provide additional guidance to health
care providers dealing with patients’
employment issues.
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